Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

#8482;; the timing of the announcement of clinical results and potential regulatory filings by Baxter Healthcare for BAX 855; the timing of availability of topline overall survival data for the NKTR-102 BEACON study; and the value and potential of our technology and research and development pipeline. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, (i) our drug candidates and those of our collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in previous preclinical and clinical studies; (ii) the timing of the commencement or end of clinical trials and the commercial launch of our drug candidates may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iii) acceptance, review and app
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 , ... Dr. Ra from Biostar , Published in ,Stem ... increase of lifespan through multiple IV administration of Adipose-derived ... and life expectancy found , Commercialization within 5 ... determined the possibility that adult mesenchymal stem cells (MSCs) ...
(Date:8/28/2015)... -- The global mHealth market ... 2020, growing at a CAGR of 47.6% from 2013 ... View Research, Inc. Monitoring services is expected to grow ... 2020.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ... of chronic diseases such as cancer, heart ailments, and ...
(Date:8/27/2015)... WASHINGTON , Aug. 27, 2015 ... Collaborative (BPC) applauds the U.S. Food and Drug ... a distinguishable name in its draft guidance issued ... of biological products proposes distinguishable names, calling for ... includes an FDA-designated suffix. This proposal reflects the ...
Breaking Medicine Technology:Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2
... Dec. 5, 2011  At this week,s 46th Annual Midyear ... Health-System Pharmacists (ASHP), Cardinal Health launched BarCode360™ , ... making it easier, more timely and cost efficient to ... scanned at the patient bedside. ASHP has ...
... Pharmaceutical Co. Ltd, in which European healthcare venture capital ... as one of the Deloitte & Touche,s 50 top-performing ... the past three years. Beijing-headquartered GC-Rise, which ... revenues rising more than 270% on average per annum ...
Cached Medicine Technology:Cardinal Health Launches Innovative Barcode Administration Solution to Help Hospitals Bridge Gaps in Medication Safety 2Cardinal Health Launches Innovative Barcode Administration Solution to Help Hospitals Bridge Gaps in Medication Safety 3Women Health Expert GC-Rise Listed in Deloitte's 50 Top-performing Companies 2
(Date:8/28/2015)... ... August 28, 2015 , ... ... for its adolescent residential, counseling, day treatment and intensive family based services. , ... standards for quality and its pursuit of excellence. As a nonprofit charity for ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... at a low cost. Personalized with practice contact information and logos, Calendars stand ... offices can also incorporate Calendars into seasonal mailings, thank you and welcome communications, ...
(Date:8/28/2015)... ... ... Northridge dentists Dr. Elyson and Dr. Assili are now offering patients ... a one hour treatment of this teeth whitening option. Zoom whitening is ... features that can turn teeth up to nine shades whiter. Effective on a wide ...
(Date:8/28/2015)... ... August 28, 2015 , ... SharkNinja, an ... coffee connoisseur and Emmy-nominated actress, Sofia Vergara, and unveil the Ninja® brand’s ... Extraction™ technology, which delivers a variety of sizes and styles while achieving the ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... is dedicated to distributing health information technology innovation to transform quality and efficiency ... of the survey will be de-identified and aggregated before being publicly shared to ...
Breaking Medicine News(10 mins):Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 3Health News:WEDI's The Sullivan Institute for Healthcare Innovation Releases Gaps in Care Survey 2
... Acute Myelogenous Leukemia (AML) and those experiencing bone marrow ... transplantation graft failure or engraftment delay,- Bayer will replace current ... supplies of Leukine to current levels as ... HealthCare Pharmaceuticals,Inc. announced today, following consultation with the United States ...
... 23 InterMune, Inc.,(Nasdaq: ITMN ) today announced ... will present at the 2008 Wachovia Healthcare,Conference in Boston ... To access a live audio webcast of the presentation, ... investor relations page of InterMune,s,corporate website at http://www.intermune.com ...
... Year-Round Campaign Continues to Benefit the National Breast ... ... to underbanked,customers, demonstrated desire to adopt and contribute to a cause, ... United,States, and ACE Cash Express, a leading retailer of financial services,have ...
... Alice S. Fisher of the Criminal Division and ... of Florida announced today that,owners of nine separate ... terms within the past two weeks. Collectively, the ... worth of,unnecessary durable medical equipment (DME) and infusion ...
... interdisciplinary team reports the design of chimeric ... for potential application in biomedical research. , ... stage where domains that traditionally belonged to ... are coming together to offer new synergistic ...
... Fewer deaths, heart attacks found in 18-month study , , WEDNESDAY, ... risk of death and heart attacks than stents for people ... study indicates. , The finding is far from the last ... author Dr. Edward L. Hannan, associate dean for research at ...
Cached Medicine News:Health News:Bayer Establishes US Special Access Program for Leukine(R) While Replacing Current Liquid Formulation 2Health News:Bayer Establishes US Special Access Program for Leukine(R) While Replacing Current Liquid Formulation 3Health News:Bayer Establishes US Special Access Program for Leukine(R) While Replacing Current Liquid Formulation 4Health News:InterMune to Present at the 2008 Wachovia Healthcare Conference 2Health News:NetSpend(R) and ACE Cash Express Customers Keep Thinking Pink With the All-Access(R) Visa(R) Prepaid Card Program 2Health News:NetSpend(R) and ACE Cash Express Customers Keep Thinking Pink With the All-Access(R) Visa(R) Prepaid Card Program 3Health News:NetSpend(R) and ACE Cash Express Customers Keep Thinking Pink With the All-Access(R) Visa(R) Prepaid Card Program 4Health News:Nine Miami Defendants in Strike Force Cases Sentenced for $56.5 Million in Medicare Fraud 2Health News:Nine Miami Defendants in Strike Force Cases Sentenced for $56.5 Million in Medicare Fraud 3Health News:Nine Miami Defendants in Strike Force Cases Sentenced for $56.5 Million in Medicare Fraud 4Health News:Engineering chimeric polypeptides to illuminate cellular redox states 2Health News:Surgery Better Than Stents for Multiple Blockages 2Health News:Surgery Better Than Stents for Multiple Blockages 3
... The Chemcard Glucose Test is a simple, ... abnormally high fasting plasma glucose (blood sugar) levels ... Chemcard Glucose is a 3 minute test which ... a fingerstick, requires no instruments, and was shown ...
The Lifestream Plus Cholesterol Monitor provides you with a comprehensive tool to help you monitor your cholesterol as part of your wellness program....
CardioChek™ PA Portable Whole Blood Test System...
... A(ll) Test is a lateral ... rapid, qualitative detection of Group ... swabs. The test is intended ... in the diagnosis of Group ...
Medicine Products: